US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

— We have everything you need: full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

Food - Microbial contamination ? SalmonellaDistribution: British Columbia See the affected products and product photos for this recall Media and public enquiries SOURCE Canadian Food Inspection Agency ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

The nine activists from Ultima Generazione who, in May 2023, poured black liquid - made from vegetable charcoal - into the ...

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...